Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

PHASE2CompletedINTERVENTIONAL
Enrollment

253

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Sarcopenia
Interventions
DRUG

REGN1033 (SAR391786)

DRUG

placebo

Trial Locations (43)

Unknown

Anniston

Phoenix

El Cajon

Garden Grove

Laguna Hills

San Francisco

Walnut Creek

Aurora

Gainesville

Jacksonville

Jupiter

Orlando

South Miami

Chicago

Baton Rouge

College Park

Elkridge

Boston

Edina

Omaha

Albuquerque

High Point

Winston-Salem

Athens

Columbus

Duncansville

Spartanburg

Dallas

Plano

San Antonio

Salt Lake City

West Jordan

Richmond

Limoges

Montpellier

Saint-Etienne

Toulouse

Amsterdam

Leeuwarden

Noord-Brabant

Albacete

L'Hospitalet de Llobregat

Madrid

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01963598 - Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia | Biotech Hunter | Biotech Hunter